The revelations contained in these documents are quite interesting, and will likely prove relevant to Pradaxa lawsuits.
New York, New York (PRWEB) February 08, 2014
As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to move forward, Bernstein Liebhard LLP notes that documents recently unsealed in the U.S. District Court, Southern District of Illinois, have shed new light on Boehringer Ingelheim’s marketing of the blood thinning drug. According to a report from The New York Times, many of the newly-unsealed emails, memos and internal presentations pertained to a study that some at the German-based company feared would raise questions about claims that Pradaxa, unlike rival warfarin, would not require patients to undergo frequent blood tests to ensure it was working.*
Among other things, the research paper in question reported that some Pradaxa patients absorbed too little of the drug for it to be effective. Other patients were found to absorb too much, putting them at risk for life-threatening episodes of Pradaxa bleeding, the Times said. The emails detailed by the article include one from a Boehringer Ingelheim supervisor who raised concerns that those findings would make it difficult for the company to defend its long-held position regarding the monitoring of Pradaxa patients. Some of the documents seem to indicate that personnel at Boehringer Ingelheim pressured the author of the study to revise it, while others suggested it should quashed altogether.
“The revelations contained in these documents are quite interesting, and will likely prove relevant to Pradaxa lawsuits. Among other things, these lawsuits question marketing claims regarding Pradaxa’s purported superiority over warfarin,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who may have been harmed by Pradaxa.
According to court documents, more than 2,100 Pradaxa lawsuits are now pending in the Southern District of Illinois that allege use of the blood-thinner caused patients to suffer uncontrollable internal bleeding. Among other things, plaintiffs claim that Boehringer Ingelheim failed to warn to doctors and patients that there was no readily available antidote for Pradaxa bleeding. Bleeding from warfarin, by contrast, can be stopped via the administration of vitamin K. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
The documents profiled by The New York Times report were unsealed via an Order issued by U.S. District Judge David Herndon on January 29th. In deciding to unseal the documents, Judge Herndon wrote that Boehringer Ingelheim had not sufficiently explained why it had marked the files as confidential.
This past April, the Institute of Safe Medicine Practices reported that Pradaxa had been named in more than 3,200 adverse event reports to the U.S. Food & Drug Administration (FDA) in 2012, the most of any drug monitored by the agency.** The New York Times report noted that the drug has now been associated with 1,000 deaths.
Pradaxa patients who have allegedly suffered serious episodes of internal bleeding due to their use of this medication may be entitled to compensation. To learn more about filing a Pradaxa lawsuit please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.
*nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html?_r=0, The New York Times, February 5, 2014
**ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com